Dr. Xiang earned his B.S. in pharmaceutics from Peking University and M.S. in Pharmacy from National University of Singapore. In 2008, Dr. Xiang moved to Finland to pursue his Ph.D degree in the Department of Clinical Pharmacology, University of Helsinki. He joined Fudan University as an associate professor in 2012. He has also worked in CombinatoRx Singapore being responsible for preclinical studies of drug development, and in National Cancer Centre Singapore with a focus on clinical trials of pharmacogenomics and pharmacokinetics. Dr Xiang’s current research focus is pharmacogenomics, drug-drug interaction, and PBPK modelling. He has been awarded 5 research grants as PI. Till now, he has published 21 peer-reviewed papers in the field of clinical pharmacology and drug metabolism.
Physiologically based pharmacokinetic modeling; Pharmacogenomics; Drug-Drug interaction; Personalized drug therapy; Bioanalysis
Education
Ph.D., Clinical Pharmacology 2008-2012 Dept. of Clinical Pharmacology, University of Helsinki, Finland
Master, Pharmacy 2002-2005 Dept. of Pharmacy, National University of Singapore, Singapore
Master, Pharmaceutics 1999-2002 Dept. of Pharmaceutics, Shanghai Institute of Pharmaceutical Industry, China
Bachelor of Science, Pharmacy 1995-1999 School of Pharmaceutical Sciences, Peking University, China
Professional Experiences
Associate Professor, 8/2012-present, School of Pharmacy, Fudan Univeristy
Associate scientist, 2/2007-12/2007, CombinatoRx Pte. Ltd. (NASDQ listed), Singapore
Research officer, 7/2005-2/2007, Laboratory of Clinical Pharmacology, National Cancer Centre Singapore, Singapore
Teaching Activities
1. Advisor for master students (Clinical Pharmacy)
2. Coordinator for graduate program in department of clinical pharmacy
3. Coordinator for exchange student program in department of clinical pharmacy
4. Courses in charge for undergraduate students: Science and humanity in drug discovery and development
Grants & Projects
2018, the Shanghai Science and Technology Committee (STCSM) research fund, “Replacement of rats in pharmacokinetic study based on PBPK modeling and Bio-PK/PD systems”, 300,000 Chinese yuan, Principal Investigator.
2018, MHHFDU-SPFDU Joint Research Fund, “Precise combined use of atorvastatin and voriconazole based on PBPK model”, 100,000 Chinese yuan, Principal Investigator.
2018, PDH-SPFDU Joint Research Fund, “Application of PBPK model in the bioequivalence study of risperidone orodispersible films”, 100,000 Chinese yuan, Principal Investigator.
2014, National Natural Science Foundation of China, “Prediction of the effect of CYP3A5 polymorphism on pharmacokinetic interaction between Wuzhi capsule and tacrolimus using PBPK modeling”, 680,000 Chinese yuan, Principal Investigator.
2012, Startup grant of Fudan University, “Application of PBPK in personalized drug therapy”, 200,000 Chinese yuan, Principal Investigator.
2010, Biomedicum Helsinki Foundation, “Effects of genetic polymorphisms in SLCO1B1 and CYP7A1 on plasma bile acids in humans and the pharmacokinetics of therapeutic ursodeoxycholic acid”, 5000 euros, Principal Investigator.
2000-2002, Study on brain-targeting formulations of trybizine hydrochloride, funded by “Innovative Drug Development Foundation” from Shanghai Institute of Pharmaceutical Industry, 100,000 Chinese yuan, Principal Investigator.
Memberships
1. Commission of Quantitative Pharmacology Committee of Chinese Pharmacology Association
2. Young Commission of Drug Metabolism Committee of Chinese Pharmacology Association
3. Commission of Drug Metabolism Committee of Shanghai Pharmacology Association
Selected Publications
1. Novel in vitro dynamic metabolic system for predicting the human pharmacokinetics of tolbutamide. Xue CF, Zhang Z, Jin Y, Zhu B, Xing JF, Ma G, Xiang X, Cai WM.Acta Pharmacol Sin. 2018 Apr 12. doi: 10.1038/aps
2. Quantification of desoxyrhapontigenin (4-methoxyresveratrol) in rat plasma by LC-MS/MS: Application to pre-clinical pharmacokinetic study.Dai Y, Tan ALC, Chen H, Ong PS, Xiang X, Wu J, Lin HS.J Pharm Biomed Anal. 2018 May 10; 153:95-101.
